Open Access
Review
Pharmacotherapy and herbal treatment of benign prostatic hyperplasia
Jianming Sun1,*,Xiaoping Zhang2
1
Shanghai Seventh People's Hospital, Shanghai, China
2
Department of Nuclear Medicine, 10th People’s Hospital, Tongji University, Shanghai, China
DOI: 10.2741/4246 Volume 19 Issue 5, pp.789-797
Published: 01 January 2014
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
*Corresponding Author(s):  
Jianming Sun
E-mail:  
sunjm67@yeah.net
Abstract

Benign prostatic hyperplasia (BPH) is the most common tumor in aging men, and is associated with lower urinary tract symptoms (LUTS). Treatment options include watchful waiting, life-style modification, pharmacologic treatment, and surgery. Alpha-adrenergic receptor blockers (α-blockers) decrease LUTS and increase urinary flow rates in men with symptomatic BPH. 5- Alpha-reductase inhibitors (5-ARIs) decrease the production of dihydrotestosterone within the prostate, which results in decreased prostate volume. For patients with moderate to severe symptoms and a large prostate, combination therapy with α-blockers and 5-ARIs can further improve clinical efficacy of treatment. Numerous plant-based products (phytomedicines) are increasingly used as an alternative or complement the conventional medication. For some patients, phosphodiesterase-5 inhibitors (PDE5-Is) or antimuscarinic agents may be added. Here, we discuss the current pharmacotherapy of BPH.


Key words

Benign prostatic hyperplasia; lower urinary tract symptoms; pharmacotherapy; Western medicine; Chinese herbal medicine, Review

Share and Cite
Jianming Sun, Xiaoping Zhang. Pharmacotherapy and herbal treatment of benign prostatic hyperplasia. Frontiers in Bioscience-Landmark. 2014. 19(5); 789-797.